OPTN Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

122.08M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

151.49M

EV/OCF(TTM)

--

P/S(TTM)

10.12

OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Show More

Events Timeline

(ET)

2025-05-21

08:28:36

Paratek Pharmaceuticals completes acquisition of Optinose

2025-03-26 (ET)

2025-03-26

07:02:22

Optinose reports Q4 EPS (3c) vs ($1.33) last year

2025-03-21 (ET)

2025-03-21

06:12:28

Optinose downgraded to Neutral from Buy at H.C. Wainwright

2025-03-20 (ET)

2025-03-20

08:44:48

Optinose downgraded to Hold from Buy at Lake Street

2025-03-20

05:52:05

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

2025-01-15 (ET)

2025-01-15

06:01:56

Optinose reports preliminary Q4 XCHANCE revenue $22.4M

2024-12-26 (ET)

2024-12-26

06:01:14

Optinose announces 1-for-15 reverse stock split

News

an image of Newsfilter

2025-05-21Newsfilter

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

an image of Benzinga

2025-05-19Benzinga

HC Wainwright & Co. Reiterates Neutral on OptiNose, Maintains $9 Price Target

an image of NASDAQ.COM

2025-05-15NASDAQ.COM

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

an image of Yahoo Finance

2025-05-14Yahoo Finance

OptiNose: Q1 Earnings Snapshot

an image of Globenewswire

2025-04-30Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

an image of Globenewswire

2025-04-17Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, OPTN, AZEK, MESA on Behalf of Shareholders

3 Analyst Rating

Wall Street analysts forecast OPTN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPTN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

HC Wainwright & Co.

Matthew Caufield

Strong Buy

to

Hold

Downgrades

$18 → $9

Al Analysis

2025-03-21

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$18 → $9

Al Analysis

2025-03-21

Downgrades

Strong Buy

to

Hold

Reason

Piper Sandler

David Amsellem

Buy

to

Hold

Downgrades

$15 → $9

2025-03-21

Reason

Piper Sandler

David Amsellem

Price Target

$15 → $9

2025-03-21

Downgrades

Buy

to

Hold

Reason

Piper Sandler downgraded Optinose to Neutral from Overweight with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OPTN

Unlock Now

Valuation Metrics

The current forward P/E ratio for OptiNose Inc (OPTN.O) is -3.63, compared to its 5-year average forward P/E of -3.99. For a more detailed relative valuation and DCF analysis to assess OptiNose Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-3.99

Current PE

-3.63

Overvalued PE

-2.01

Undervalued PE

-5.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-13.63

Current EV/EBITDA

241.48

Overvalued EV/EBITDA

44.65

Undervalued EV/EBITDA

-71.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

1.88

Current PS

0.92

Overvalued PS

2.64

Undervalued PS

1.13

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is OptiNose Inc (OPTN) stock price today?

The current price of OPTN is 0 USD — it has increased 0 % in the last trading day.

What is OptiNose Inc (OPTN)'s business?

OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

What is the price predicton of OPTN Stock?

Wall Street analysts forecast OPTN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPTN is9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is OptiNose Inc (OPTN)'s revenue for the last quarter?

OptiNose Inc revenue for the last quarter amounts to 18.51M USD, increased 24.40 % YoY.

What is OptiNose Inc (OPTN)'s earnings per share (EPS) for the last quarter?

OptiNose Inc. EPS for the last quarter amounts to -1.92 USD, increased 2.67 % YoY.

How many employees does OptiNose Inc (OPTN). have?

OptiNose Inc (OPTN) has 127 emplpoyees as of January 17 2026.

What is OptiNose Inc (OPTN) market cap?

Today OPTN has the market capitalization of 122.08M USD.